Improved tumor targeting by combined use of two antitenascin antibodies.
Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A, Leoni B, De Angelis C, Paganelli G, Palombo G, Dani M, Carminati P, De Santis R.
Petronzelli F, et al. Among authors: de angelis c, de santis r.
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7137s-7145s. doi: 10.1158/1078-0432.CCR-1004-0007.
Clin Cancer Res. 2005.
PMID: 16203813